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Previous reports (1, 2, 3) have suggested that the Epstein-Barr virus (EBV) 
induces the appearance  of antigens on the surface of cells cultured from Bur- 
kitt's  lymphomas  (BL)  or  peripheral  leukocytes  from  patients  in  the  acute 
stage of infectious mononucleosis (IM). Various observations indicated that the 
cell membrane  antigens are distinct from EB virion antigens.  Most notable is 
the  fact  that  sera  were  found  which  reacted  predominantly  with  the  cell 
surfaces, and little or not at all, with EBV antigens. This type of reactivity was 
found thus far only among sera from relatives of Burkitt  tumor patients.  The 
converse "discrepancy", high anti-EBV titers, but insignificant interaction with 
cell  membrane  antigens,  was  also noted  in  a  few sera.  The present  report  is 
concerned with an analysis of such differential serological activities. 
Materials and Methods 
Cdls.--The establishment  and maintenance  of cell cultures  derived from Burkitt tumor 
biopsies and peripheral leukocytes of IM patients  have been previously described (4, 5). 
Immurwfluoresceme Tests.--The techniques for detection  of antibodies  to cell membrane 
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antigens and for the titration of anti-EBV reactivity have been described (5-9).  1 The results 
of indirect membrane fluorescence, using a fluorescein-conjugated goat anti-human gamma 
chain reagent (Hyland Laboratories, Los Angeles, Calif.), are expressed in terms of fluores- 
cence indices (FI) which were calculated by the established formula (1). Blocking  tests were 
performed, using reagents prepared for direct membrane fluorescence by a previously de- 
scribed conjugation procedure.  1 The results of these experiments are expressed as blocking 
indices (BI) and are calculated as previously reported (3).  1 Membrane antibody titers were 
determined by indirect fluorescence. The serum dilution giving a FI of 0.3 was taken as the 
titer end point. 
Serum Absorptions.--1 ml of Mutua serum (3) diluted 1:40 was absorbed 5 X with a total 
of 7.5 X 107 cultured BL cells. Absorption was done at 37°C for 1 hr, followed by overnight 
at 4°C. 
RESULTS 
Indirect  Immunofluorescence  Tests.--Sera  from  nine  relatives  of  Burkitt 
tumor  patients  (eight  siblings,  one  father)  revealed  low  anti-EBV  levels 
(~ 1:10), yet gave significant indirect membrane immunofluorescence (MIF) 
reactions,  both  when  BL  and  1-1VI cells  were  used  as  targets.  In Fig.  1  the 
titers obtained in the MIF test with eight of these discrepancy sera are plotted 
against the anti-EBV titers.  Also included in the figure, for comparison, are 
corresponding data obtained with sera from patients with BL, IM, and cancer 
of the postnasal space (Ca PNS). Whereas the MIF titers of sera from the three 
types of patients  showed a  good correlation with  their  anti-EBV levels,  the 
sera from BL relatives clearly did not fall into this pattern. 
Fig. 2 compares the MIF reactivity of the undiluted BL  relative  sera  with 
the  activity of  the  undiluted  standard  BL  patient  Mutua  serum.  The per- 
centage of cells  reacting with Mutua serum has been plotted against the per- 
centage of cells  which react with the various BL relative sera,  tested  at the 
same  time  against  the same  target  cells  by the  indirect  MIF  test,  using  a 
goat anti-human heavy chain reagent.  The spectrum of  target  cells  used  in 
those tests were derived from membrane-reactive or nonreactive BL and IM 
cell lines.  As described previously  (1),  cells  of  these  various  lines  do  or  do 
not react with Mutua serum,  depending  on  the  extent  of  the  EBV  carrier 
state,  as well  as periodic fluctuations in the persistent infection. The reasons 
for the fluctuations are unknown but appear to depend on the age and condi- 
tion  of  the  cultures.  It can be seen that there was a  direct  relationship be- 
tween the reactivity of the various  cells  with  the  Mutua  serum  and  their 
reactivity  with  the  various  discrepancy sera tested,  although the  percent- 
ages of cells  stained  by the latter  were  often  somewhat  lower  than  those 
obtained  with  Mutua  serum.  This indicated that although essentially anti- 
EBV-negative, the various BL relative sera  contained  antibodies  capable  of 
reacting with the membranes of BL and IM ce]Is in  a way similar  to the re- 
activity of the Mutua serum. 
1 Goldstein, G., G. Klein, G. Pearson, and P. Clifford, 1958. Direct membrane immuno- 
fluorescence reaction of Burkitt lymphoma  cells in culture. Cancer Res. In press. s. 
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Blocking Tests Against F-Mu~u¢ (Ftuor~cein-Conjuga~t Globulin of Mutua' s 
Serum).--To investigate further the specificities of the described reactions, sera 
from relatives of BL patients were tested for blocking activity against F-Mutua. 
The BI values plotted against anti-EBV titers are shown in Fig. 3, chart A. 
For comparison, the BI values of the BL, IM, and Ca PNS sera used in Fig. 1 
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Fro. 1. Indirect membrane immunofluorescence  and anfi-EBV titers of sera from relatives 
of BL patients as compared to some BL, IM, and Ca PNS reference sera. 
are also plotted against their anti-EBV fiters to iUustrate the usual relationship 
between BI and anfi-EBV values. As mentioned earlier, the BL relative sera 
were negative or low with regard to their level of antibodies to EBV, with one 
notable exception (not included in the previous test), which revealed an anti- 
EBV titer as high as found in most Burkitt patients' sera (3). This serum also 
showed a very high blocking activity, whereas the sera with no or low anti-EBV 
activity in this category showed only relatively low  (BI of 0.2-0.5)  or insig- 
nificant blocking. Two sera from other categories also seemed to fall outside 710  EB  VIRAL  AND  CELL MEMBRANE, TMMUNOFLUORESCENCE. IV 
the usual pattern. These had high anfi-EBV fiters but low blocking activity 
and came from patients with Ca PNS (10). The possible significance of these 
sera will be discussed later. 
The weak blocking of F-Mutua  by BL  relative sera  as  compared to  the 
strong reactivity of sera from patients with BL and certain cases of Ca PNS 
raised the question whether qualitative or quantitative differences in antibodies 
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FIG.  2.  Indirect membrane immunofluorescence reactivity of EBV-negative, membrane- 
positive BL patients' relative sera compared with the reactivity of Mutua serum against the 
same spectrum of reactive and nonreactive BL and IM cells. Goat anti-human gamma chain 
reagent was used in these tests. 
were responsible for the  differential behavior of the  sera.  This question was 
explored by plotting the MIF titers of the various sera against their blocking 
indices (Fig. 3, chart B). It appeared that the MIF titers of sera, other than 
those from relatives of BL patients, with two exceptions, were directly related 
to their BI values, since the mean titers seemed to fall into a narrow band. The 
sera of the relatives also conformed to some extent to this pattern, although 
their BI values generally fell into the lower ranges for given MIF titers, and in 
two cases were well below the ranges observed. The four sera which clearly fell 
outside this pattern all had MIF titers of _-__  1: 80, yet failed to block F-Mutua 
staining in a significant manner. The two sera from BL relatives had anti-EBV 
titers of =< 1 : 10. The other two sera, derived from patients with Ca PNS, had J,O  " 
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FIG.  3.  Rdationship between the blocking  activity  (BI),  against  Mutua conjugate,  of 
representative sera of the various categories indicated, and (A) anti-EBV titer0 and (B) in- 
direct membrane immunofluorescence titer. 
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auti-EBV titers  of 1:320 and  1:640,  respectively,  and were in fact the  same 
sera which failed to show the usual correspondence between anti-EBV and BI 
reactivities  (Fig.  3,  chart A).  These results  revealed  that MIF  and  BI reac- 
tivities do not necessarily parallel each other. 
Blocking Tests witk F-Robert.--The above observations indicated the need of 
FITC conjugates prepared from sera of BL relatives for blocking tests.  Cor- 
respondingly, the gamma globulin of an 18 year old relative, Robert N. (brother 
TABLE I 
Summary of Blocking  Tests with BL Relative Sera against F-Mulua and F-Robert Compared 
with Anti-EBV and MIF Titers of Same Sera 
Name 
Mutua  N. 
Robert N. 
Beth N. P. 
0gunda  M. 
Salim  M. 
Sophia  A. 
Zacharia M. 
Wanambisi 
Befit 
Lameck W. 
Proud 
Status 
Burkitt's lymphoma 
BL relative 
BL relative 
BL relative 
BL relative 
BL rdative 
BL relative 
BL relative 
Control (Swedish) 
Embryonal sarcoma 
(African) 
Isoantiserum  (French) 
A 
Titers 
lti-EBV  MIF* 
160  >80 
<10~ 
40  >8O 
<10  -20 
<10  40 
< 10  10 
<10  >80 
<10  ~10 
10  40 
20  N.T. 
< 10  N.T. 
5-40  N.T. 
BI 
F-Mutua  F-Robert 
0.78  0.90 
0.26  0.91 
0.35  0.75 
0.35  0.73 
0.30  0.94 
0.31  0.54 
0.14  0.15 
0.40  0.73 
0.16  0.17 
0.05  0.00 
0.10  0.00 
* FI, 0.3 as titer end point. 
:~ Anti-EBV values from two separate serum samples. 
§ Not tested. 
of Burkitt  patient  Fanis A., Kenya  Cancer  Council  [K.C.C.]  No.  300),  was 
conjugated  with  FITC  and  used  for  direct  membrane  fluorescence  and  for 
blocking tests.  When unconjugated and used in the indirect fluorescence test, 
this serum showed, with a similarity to the membrane-positlve BL relative sera, 
a  reactivity against different cell lines that closely paralleled  the reactivity of 
the  same cells  with  Mutua's  serum  in the  indirect  test,  as shown in  Fig.  2. 
This serum was also tested  for isoantibodies  by leukocytotoxicity against 37 
cell donors. The results were negative,  s When the stainability of different target 
cells with the fluorescein-conjugated globulin of Robert N.'s serum, F-Robert, 
was compared with the staining of the same cells with  F-Mutua,  a  generally 
2 Terasaki,  P. I. Personal communication. PEARSON  ET  AL.  713 
good correlation was obtained. This finding is in agreement with the results of 
the indirect  test  (Fig.  2). Thus the antibodies present in Robert's serum are 
directed against antigen(s) present on BL and IM cells, the expression of which 
is also demonstrated by Mutua's serum. 
Blocking tests, using F-Robert and various types of sera, revealed that six 
sera from BL and three sera from Ca PNS patients tested were strongly posi- 
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FIO. 4. Comparison of anti-EBV and MIF titers of Mutua serum before and after absorp- 
tion with membrane-reactive BL cells. A fluorescence index (FI) of 0.3 was taken as the end 
point for determining the indirect membrane immunofluorescence (MIF) titer. 
tive, whereas  among 11  control sera from African patients,  with  or without 
neoplastic disease,  eight were negative  and  three  showed  limited  extents  of 
blocking. It is significant that six of seven BL relative sera examined strongly 
blocked F-Robert (Table I). Of special interest is the fact that no blocking was 
obtained  with  an  isoantiserum  from  a  multiply  transfused  French  patient 
(Proud) which was previously found to react with all target ceils in the indirect 
MIF test (7). In contrast to the above results with F-Robert, the BL relative 
sera blocked staining by F-Mutua only to minor or insignificant extents. These 
results indicate that the serum of Robert shares antibodies with the serum of 
Mutua,  but  that  Mutua's  serum  contains  additional  antibodies  which  are 
either  absent  in  Robert's serum or present  at  insufficient  levels to  compete 714  EB  VIRAL  AND  CELL  mEMBRANE  1MMUNOFLUORESCENCE.  IV 
with Mutua's  serum,  since F-Mutua is not blocked by Robert's serum. The 
antibody present in Robert's serum appears to be present also in sera of other 
relatives of BL patients. 
Demonstration of Sera with High A nti-EB V and Low Blocking Activity Agaimt 
Conjugated Mutua Serum.--As  shown  earlier in  this paper,  as well as in the 
preceding paper of this series (3), several sera were observed with high anti-EBV 
activity but low ability to block the direct membrane staining by the Mutua 
conjugate. It was conceivable that these sera, some of which were positive in 
indirect MIF  tests,  may contain part but not all  of the antibody spectrum 
present in Mutua's serum, since they did not block F-Mutua.  Alternatively, 
their antibody activity may be  absent from the  Mutua  conjugate.  It is  of 
interest that two of the sera which were also tested for blocking activity against 
F-Robert showed higher BI activity against this reagent than against F-Mutua. 
Since exceptional sera may permit further dissection of the serological interac- 
tions, such  sera are  being searched for and studied in more detail in  cross- 
blocking experiments which are presently in progress. 
Serum Absorption Experiments.--To provide further evidence that the anti- 
bodies involved in the anti-EBV and membrane immunofluorescent reactions 
are  distinct,  Mutua  serum was  absorbed with  cultured Burkitt  tumor  cells 
that had been pretested with F-Mutua for MIF antigens. The absorbed serum 
was  then titrated for antibodies  to both EBV and membrane antigens.  The 
results of this experiment are shown in Fig. 4. If the dilutions of the absorbed 
and unabsorbed serum which gave MIF indices of 0.3 were compared, it was 
seen that the MIF titer of the absorbed serum had decreased approximately 
64-fold, whereas the anti-EBV titer had declined only about 3-fold. 
DISCUSSION 
Recent  results  (3)  have  established  that  sera  from  most  patients  with 
Burkitt's  lymphoma,  infectious  mononucleosis,  and  certain  patients  with 
nasopharyngeal cancer contain antibodies directed against  the membranes of 
cells  from EBV-carrying cultures,  as  well  as  against  EBV  itself.  However, 
discrepancies have been noted which have suggested that two different types of 
antigens and antibodies are involved in the two tests. The results of experiments 
reported in this paper tend to provide further support for this suggestion. 
The most  convincing evidence was provided by absorption of the Mutua 
serum with membrane-antigen-positive BL cells.  Membrane activity was re- 
moved without significantly affecting the anti-EBV titer of the serum. 
Further evidence was provided when donors of sera containing high anti- 
membrane but low anti-EBV activities were found among relatives of Burkitt 
patients. The antibody specificities of these sera were studied extensively by 
both indirect and blocking of direct membrane immunofluorescence techniques. 
The results suggest that  the antibodies found in the serum of Mutua,  a  BL PEARSON ET AL.  715 
patient,  share  at least some specificities  with  antibodies found in  these  sera. 
This was established  by demonstrating a  correspondence of stainable cells  in 
indirect and direct membrane immunofluorescence tests on the various target 
ceils  and  in  blocking  experiments  against  F-Mutua  and  a  conjugated  BL 
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relative serum, F-Robert. These sera did not block the F-Mutua, or blocked it 
only to insignificant or partial extent. F-Robert, on the other hand, was blocked 
by the sera of BL relatives  and by Mutua,  but not by various control sera 
which included an isoantiserum,  thereby establishing a partial identity among 
the blocking sera. These blocking patterns established for sera from BL patients 
and BL relatives against F-Mutua and F-Robert are presented in Fig. 5. 
It is interesting to note that although Robert serum did not block F-Mutua, 
Mutua serum did block F-Robert. Since Robert had a MIF titer of ~  1: 80, the 716  EB  VIRAL  AND  CELL  MEMBRANE  IMMUNOFLUOI~ESCENCE.  IV 
failure of Robert to block Mutua would not appear to be explained by quantita- 
tive but more likely by qualitative factors. One possible explanation for this 
paradox is that Mutua serum contained anti-membrane antibodies of more than 
one specificity. If this were true, and Robert lacked one of these specificities, 
one  would  not expect  Robert to block  F-Mutua, but Mutua should block 
F-Robert. This might also be the explanation for the failure of some strongly 
EBV- and MIF-positive sera to block F-Mutua. This interpretation obviously 
requires further substantiation. 
Sera  with positive  MIF but low or no anti-EBV activities might denote: 
(a) that in rare instances the viral genome persists in some cells without replica- 
tion of infectious virus but induces surface antigens in some ceils or (b) that an 
antigenically distinct herpes group virus induces similar antigens. It would be 
difficult to see how interpretation (b)  could  account for the involvement of 
relatives  of BL patients in this type of discrepancy.  Interpretation (a)  could 
denote that the virus persists in certain healthy individuals in a "nonvegeta- 
tive" form which  is nevertheless  capable  of inducing surface  antigens. This 
might happen, perhaps  particularly, in direct patient contacts, although the 
significance of patient contact for this type of serum reactivity remains to be 
investigated further, using carefully matched controls. 
The opposite discrepancy,  sera with high anti-EBV levels that fail to block 
the Mutua conjugate might indicate: (a) that the presence in an individual of 
numerous cells with surface antigens absorbs the corresponding antibody from 
the serum and body fluids. This situation might occur in patients with car- 
cinoma of the postnasal space, provided that the cells of this tumor also contain 
the surface antigen, just as does the surface of Burkitt lymphoma cells. The 
same might hold occasionally for patients with large, rapidly growing recurrent 
Burkitt~s lymphomas (3);  or (b)  that too few cells with surface  antigen are 
present to keep the corresponding antibodies at levels sufficient for their detec- 
tion. This might occur in infectious mononucleosis where the bulk of the anti- 
gen-containing  cells may disappear  after temporary proliferation.  Anti-EBV 
titers are less subject to fluctuations and persist for indefinite periods of time. 
There is evidence that EBV (little as may be there)  persists  not only in the 
tumors, but also in other cells of the lymphatic system. One may assume then 
that EBV is possibly more antigenic  than the surface  antigen(s),  or  alterna- 
tively, that it is largely hidden inside the ceils and less available for absorption 
of circulating  antibodies. 
Whatever the ultimate explanation,  it seems clear that the MIF and EBV 
antigens are distinct, as are the corresponding  antibodies.  Furthermore, the 
differential blocking  of F-Mutua and F-Robert by various sera suggests the 
existence of at least two membrane antigens. The question whether the surface 
antigen(s)  have any relation to malignant transformation, that is, whether the 
EBV-related surface antigen(s)  result from the action of an agent capable  of PEARSON ET AL.  717 
such transformation, or represents merely a passenger, cannot be answered at 
present. 
SUMMARY 
Previous reports (1, 2) have established that the expression of certain distinc- 
tive membrane antigen(s)  on the  surface of Burkitt's lymphoma (BL)  and 
infectious mononucleosis (IM) cells  is dependent on the presence of Epstein- 
Barr virus  (EBV)  in the cell line. The investigations reported here provide 
evidence that antibodies directed against EBV antigens,  as revealed by the 
immunofluorescence  test  on  acetone-fixed  smears  (8),  and  the  membrane 
reactive antibodies, although often present in the same serum, are nevertheless 
distinctly different. Absorption of Mutua serum, the standard reference serum 
for demonstrating membrane antigen(s)  on BL and IM cells,  with BL cells 
completely removed anti-membrane activity without significantly affecting the 
anti-EBV antibody titer. Furthermore, sera were found which contained one 
type of antibody but not the other. Sera with high anti-membrane but low 
anti-EBV  activity were  found  among relatives  of BL  patients.  These  sera 
reacted with the membranes of EBV-carrying BL and IM ceils in essentially the 
same way, i.e., against the same spectrum of target cells, as the EBV-positive 
Mutua serum. They were unable to block the membrane reactivity of FITC- 
conjugated Mutua  serum,  however.  In  some  cases  they showed  weak  but 
incomplete blocking. One such EBV-negative, membrane-positive BL relative 
serum (Robert) was conjugated with FITC and used for direct staining of BL 
and IM cells. Again, this conjugate reacted against the same target cell spec- 
trum as a  Mutua conjugate, but its reactivity was completely blocked by a 
number of Burkitt patients' sera, although unconjugated Robert serum did not 
block the Mutua-conjugate. A number of other membrane-positive BL relative 
sera also failed to block Mutua, but completely blocked the Robert conjugate. 
A  number of Swedish and African control sera and an isoantiserum gave no 
blocking against Robert conjugate. It therefore appears that the Mutua con- 
jugate contains at least two antibody specificities against the EBV-determined 
membrane  antigens.  One,  but  not  the  other,  is  shared  with  the  antibody 
specificity  present  in  Robert's  serum  and  a  number  of  other  sera  from 
relatives of BL patients. 
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